Skip to content

Study · Ex vivo tissue · 2021

2 results

Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.

Matteucci C, Minutolo A, Balestrieri E, Petrone V, Fanelli M, Malagnino V, Ianetta M, Giovinazzo A, Barreca F, Di Cesare S, De Marco P, Miele MT and 9 more

Show all authors

Toschi N, Mastino A, Sinibaldi Vallebona P, Bernardini S, Rogliani P, Sarmati L, Andreoni M, Grelli S, Garaci E

Open forum infectious diseases5 Dec 2020Cited by 28 (Europe PMC)

PMID33506065 (opens in a new tab)PMCIDPMC7798699 (opens in a new tab)DOI10.1093/ofid/ofaa588 (opens in a new tab)PepBankPUB-33506065
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueMechanism

    In blood cells from patients with COVID-19, ex vivo treatment with Tα1 mitigated cytokine expression.

    In plain wordsIn lab tests on COVID-19 blood cells, thymosin alpha‑1 reduced the expression of inflammatory signals.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCytokine expression
    Study

    humann: not reported in source

    blood cells from patients with COVID-19
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the ex vivo treatment with Tα1-mitigated cytokine expression
    1 context sentence
    Summary · context
    In this study, we captured the interconnected biological processes regulated by Tα1 in CD8+ T cells under inflammatory conditions.
  2. 02LabEx vivo tissueMechanism

    In blood cells from patients with COVID-19, ex vivo treatment with Tα1 inhibited lymphocyte activation specifically in a CD8+ T-cell subset.

    In plain wordsIn lab tests on COVID-19 blood cells, thymosin alpha‑1 reduced the activation of one type of T cell.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLymphocyte activation in CD8+ T-cell subset
    Study

    humann: not reported in source

    blood cells from patients with COVID-19
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    inhibited lymphocyte activation in a CD8+ T-cell subset specifically.
    1 context sentence
    Summary · context
    In this study, we captured the interconnected biological processes regulated by Tα1 in CD8+ T cells under inflammatory conditions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.